Lifeboat Foundation

Liz Parrish is the Founder and CEO of BioViva Sciences USA Inc. BioViva is committed to extending healthy lifespans using gene therapy. Liz is known as “the woman who wants to genetically engineer you,” she is a humanitarian, entrepreneur and innovator and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of gene therapy, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach and sits on the board of the International Longevity Alliance (ILA). She is an affiliated member of the Complex Biological Systems Alliance (CBSA) whose mission is to further scientific understanding of biological complexity and the nature and origins of human disease. She is the founder of BioTrove Investments LLC and the BioTrove Podcasts which is committed to offering a meaningful way for people to learn about and fund research in regenerative medicine. She is also the Secretary of the American Longevity Alliance (ALA) a 501©(3) nonprofit trade association that brings together individuals, companies, and organizations who work in advancing the emerging field of cellular & regenerative medicine with the aim to get governments to consider aging a disease. I am not a medical doctor or scientist. I can not answer details of therapy. I would like to discuss my experience of creating BioViva, organizing the gene therapies, and then finally being able to administer it to the first human.

Read more

Mark Pollock became blind asa young man, and was paralyzed by an accident later. Now, he is taking steps with the help of a robotic exoskeleton.

Read more

BOSTON, Sept. 29, 2015 /PRNewswire/ — Veritas Genetics today announced that the company is making it possible for participants in the Personal Genome Project (PGP) to be among the first to get their whole genome sequenced and interpreted for less than a $1,000.

Led by Veritas Genetics Co-Founder Dr. George Church, Professor of Genetics at Harvard Medical School and Director of the Personal Genome Project, PGP is a long-term effort to sequence thousands of complete genomes to enable research into personal genomics and personalized medicine. PGP has more than 16,000 participants worldwide.

The “$1,000 Genome” has long been considered the tipping point when sequencing and interpreting the human genome becomes commonplace and begins to rapidly increase what is known and to dramatically impact healthcare. The catchphrase underscores how far science has come since the actual cost of the Human Genome Project, estimated at $2.7 billion spent over a decade.

Read more

https://youtube.com/watch?v=xU8kDSTzYd4

This short video (with some fun integrated graphics) is from an interview I did with El País (the largest newspaper in Spain). It highlights some of the emerging technologies and approaches which have the potential to shift health, medicine and biopharma from an intermittent and reactive physician-centric mode, to an era of more continuous data and a proactive approach in which the individual is increasingly empowered and integrated into personalized wellness, diagnosis and therapy.

Read more

Many people may not know it but the most important risk factor for cancer is growing older. Most cancers occur in people over the age of 65.

Many people may not see cancer as an age-related disease, but it’s a major hurdle we’ll have to overcome in the pursuit of longer lives.

Read more

Fear of scientists “playing god” is at the centre of many a plot line in science fiction stories. Perhaps the latest popular iteration of the story we all love is Jurassic World (2015), a film I find interesting only for the tribute it paid to the original Michael Crichton novel and movie Jurassic Park.

Full op-ed from h+ Magazine on 7 October 2015 http://hplusmagazine.com/2015/10/07/opinion-synthetic-biolog…f-mankind/

In Jurassic Park, a novel devoted to the scare of genetic engineering when biotech was new in the 1990s, the character of John Hammond says:

Continue reading “h+ Magazine: Synthetic Biology — The True Savior of Mankind” »

Scientists in the UK and Australia have identified three biomarkers, which when they attached to T-cells (part of the immune system) in high numbers prior to anti-retroviral therapy, increase the chance of early rebound.

Read more

Artificial hearts can be clunky and flawed, but making one out of foam could be an efficient and reliable solution.

Read more

This mini device could some day save your life.

Read more